Autres langues Spyre Therapeutics, Inc.

Actions

SYRE

US00773J2024

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
33,56 ^USD	+3,36 %		+3,55 %	+55,95 %

26/03	SPYRE THERAPEUTICS, INC. : Stifel Nicolaus maintient sa recommandation à l'achat	ZM
01/03	SPYRE THERAPEUTICS, INC. : Wells Fargo Securities adopte une opinion positive	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Sector Update: Health Care Stocks Steady Pre-Bell Friday	19/04
Spyre Therapeutics Files Mixed-Securities Shelf Registration for About 33.4 Million Shares	19/04
Spyre Therapeutics Announces Grants of Inducement Awards	01/04
Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding	18/03
North American Morning Briefing : Powell Still in -2-	07/03
Spyre Therapeutics Announces Grants of Inducement Awards	04/03
North American Morning Briefing : Stock Futures -2-	04/03
Spyre Therapeutics Announces Grants of Inducement Awards	01/03
Spyre Therapeutics: Q4 Earnings Snapshot	29/02
Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Spyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	29/02
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference	26/02
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn s and Colitis Organisation	09/02
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors	06/02
Spyre Therapeutics, Inc. Announces Board Changes	05/02
Spyre Therapeutics Announces Grants of Inducement Awards	02/02
Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors	27/12
Spyre Therapeutics Announces Grants of Inducement Awards	22/12
Spyre Therapeutics Agrees to Sell Shares in Private Placement for Expected Gross Proceeds of About $180 Million	08/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Spyre Therapeutics, Inc.

Actions

SYRE

US00773J2024

Autres langues

Filtres